Section 32 Leads $75M Series B Financing of BigHat Biosciences to Design Safer, More Effective Antibodies
Gunderson Dettmer represented client Section 32, a venture capital fund that invests in frontiers of technology and healthcare, as it led the $75 million Series B financing of BigHat Biosciences. BigHat uses machine learning and synthetic biology for developing safer and more effective antibody therapies to treat some of the world’s most intractable conditions, from chronic illnesses to life-threatening diseases.
In the announcement of the transaction, managing partner of Section 32 Steve Kafka said, “BigHat is ushering the next wave of personalized medicines with a sophisticated AI platform integrated with a next-generation lab that addresses the complexities and inefficiencies associated with biologics discovery. Section 32 is delighted to support BigHat’s mission and their quest to rapidly deliver safer and more effective antibody therapies for people suffering from today’s most challenging diseases.”
The Gunderson Deal team was led by Jeff Higgins and Ryan Gunderson and included Jordan Murray, Will Fogarty and Benjamin Cohen-Kurzrock.